Prosecution Insights
Last updated: November 15, 2026
Application No. 18/177,298

PREPARATION METHOD AND APPLICATION OF NON-HUMAN MAMMALS OR THEIR PROGENIES

Final Rejection §112
Filed
Mar 02, 2023
Priority
Sep 04, 2020 — CN 202010924095.1 +1 more
Examiner
MONTANARI, DAVID A
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Beijing Life Biosciences Co. Ltd.
OA Round
2 (Final)
65%
Grant Probability
Moderate
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allowance Rate
503 granted / 777 resolved
+4.7% vs TC avg
Strong +49% interview lift
Without
With
+49.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
56 currently pending
Career history
841
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s arguments and amendments filed on 6/20/2026 have been entered. Claims 50, 52, 54, 56, 58 and 60 have been amended. Claim 64 is new. Claims 44-49 have been cancelled. In view of Applicant’s amendments the scope of enablement is withdrawn. In view of Applicants’ amendments the 112(b) rejection is withdrawn. In view of Applicant cancelling claims 44-49 the 102(a)(1) rejection is moot. In view of Applicant’s amendments the 103 rejection is withdrawn. Claims 50-60 and 64 are examined in the instant application. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 50-60 and 64 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 50 is unclear. Claim 50 comprises two separate knockout steps, the first knocking out a gene encoding IgM and IgD heavy chain constant regions and second step knocking out a nucleotide sequence encoding a CH1 domain. Claim 50 has been amended to recite that in the gene knockout step, all nucleotides sequences from the first exon of the gene encoding the IgM heavy chain constant region to the first exon of the gene encoding the IgG2c heavy chain constant region in the mouse are knocked out. Additionally the new amendment is unclear regarding which nucleotide sequences are knocked out. In line 7 claim 50 recites that a nucleotide sequence is knocked out “to the gene” encoding IgG2c… However in the new amemdment to claim 50 in n line 10, it is recited that all nucleotide sequences are knocked out “to the first exon” of the gene encoding the IgG2c heavy chain constant region. These two limitations are of different scope, and it is not clear what nucleotide sequences are thus being knocked out. Before the first “exon” encoding IgG2c are additional sequences comprising the I-exon, germline promoter and Sγ2c region that are before the first exon but are part of the IgG2c gene. Deleting these nucleotide sequences in line 10 would differ from the nucleotide sequences deleted in line 7, thus the metes and bounds of which nucleotide sequences are being knocked out is not clear in view of the new amendment to claim 50. Claim 64 is unclear. Claim 64 recites the limitation “and/or” three times in lines 3, 5 and 8. However it is not clear what the metes and bounds are of claim 64 are since there are multiple combinations of targeting sequences. Thus it is not clear which targeting sequences are used in the preparation method of claim 58. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID A MONTANARI whose telephone number is (571)272-3108. The examiner can normally be reached M-Tr 8-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. DAVID A. MONTANARI Examiner Art Unit 1632 /ANOOP K SINGH/Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Mar 02, 2023
Application Filed
Mar 30, 2026
Non-Final Rejection mailed — §112
Jun 30, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747453
GENE-THERAPY VECTORS FOR TREATING CARDIOMYOPATHY
3y 1m to grant Granted Sep 29, 2026
Patent 12742181
GENE-THERAPY VECTORS FOR TREATING CARDIOMYOPATHY
3y 8m to grant Granted Sep 22, 2026
Patent 12703854
IN VITRO METHOD OF DIFFERENTIATING A HUMAN PLURIPOTENT STEM CELL POPULATION INTO A CARDIOMYOCYTE CELL POPULATION
4y 11m to grant Granted Aug 11, 2026
Patent 12698310
COMPOSITIONS AND METHODS FOR INSECT CONTROL
5y 0m to grant Granted Aug 04, 2026
Patent 12692481
BACULOVIRUS EXPRESSION SYSTEM
6y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+49.2%)
Moderate
PTA Risk
Based on 777 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month